Kornimate/medical-research-clean huggingface dataset:
evaluation of the impact of implementing a patient blood management protocol on the transfusion rate in delivery hemorrhage

Conditions: Delivery Hemorrhage

Summary: according to the who, anemia is one of the ten most serious health problems in the world. during pregnancy, it affects 42% of women worldwide and 25% in france. it is associated with an increased risk of perinatal morbidity and mortality, and recourse to blood transfusion. the blood transfusion is itself also a source of thromboembolic morbidity and mortality, infectious diseases and pulmonary pathologies. in addition, the risk of hemorrhage, particularly during delivery, is inherent to all pregnancies and difficult to predict. since 2010, the who has defined the rational use of blood products as the 4th global priority, and the need for countries to reduce blood transfusion. it introduces the concept of patient blood management (pbm). this is a set of measures designed to manage anemia and bleeding in surgical patients, while avoiding the need for transfusion. these measures include preoperative screening for anemia and martial deficiency, iron and vitamin supplementation, intraoperative bleeding control and optimization of postoperative blood balance. recommended by several national programs, pbm has developed rapidly in orthopedic and cardiac surgery, where numerous studies have demonstrated its effectiveness, particularly in terms of transfusion savings. in obstetrics, however, the implementation of pbm remains less widespread, notably due to the difficulty of getting teams on board, and the absence of protocolization. however, given the high prevalence of anemia in pregnant women, and the inherent risk of hemorrhage in all deliveries with potential recourse to blood transfusion, personalized optimization of pbm is a major challenge in obstetrics. the pbm is currently being implemented in routine practice in the chits maternity department, in line with recommendations. in this context, our research aims to assess the impact of this new approach. our main hypothesis is that implementation of a pbm protocol would reduce the rate of transfusion in delivery hemorrhage.

from 1 january 2023 to 31 december 2025, the investigators conducted a single-center, before-and-after study at the maternity unit of the sainte musse hospital in toulon (level iib maternity unit). this is a retrospective observational study with a retrospective section covering the period before the implementation of the pbm protocol between 1 january 2023 and 31 december 2024. then a prospective part covering the period after the implementation of the pbm protocol, from 1 january 2025 to 31 december 2025.

Eligibility criteria:
inclusion criteria: * any patient who has had a delivery hemorrhage, whatever the mode of delivery exclusion criteria: * minor * under legal protection * hemoglobinopathies * patient's refusal to participate in research

Keywords: delivery hemorrhage pregnancy blood transfusion patient blood management iron supplementation gestational anemia
subcuticular skin closure at cesarean delivery

Conditions: Cesarean Section; Infection

Summary: subcuticular skin closure with suture after cesarean has been shown to result in lower rates of wound complications than with staple closure. however, the optimal choice of suture material for subcuticular skin closure is unclear. vicryl vs prolen suture materials will be used for subcuticular closure of transverse skin incisions after cesarean section. patients will be controlled for superficial surgical site infections 1 week after the cesarean section.

cesarean section is the most common abdominal surgery worldwide. subcuticular skin closure with suture after cesarean has been shown to result in lower rates of wound complications than with staple closure. however, the optimal choice of suture material for subcuticular skin closure is unclear. vicryl vs prolen suture materials will be used for subcuticular closure of transverse skin incisions after cesarean section. patients will be controlled for superficial surgical site infections 1 week after the cesarean section.

Eligibility criteria:
inclusion criteria: * age 18-40 * women undergoing cesarean section exclusion criteria: * body mass index\>30

Keywords: cesarean section; complications suture material
study evaluating workload, clinical and therapeutic management of psoriatic arthritis

Conditions: Psoriatic Arthritis

Summary: in spain, there is little data available concerning the evolution and treatment of psoriatic arthritis by rheumatologists and dermatologists. this study is designed to obtain more data about the clinical and therapeutic management of psoriatic arthritis in dermatology and rheumatology medical centers.


Eligibility criteria:
inclusion criteria: 1. patients older than 18 years with a psoriatic arthritis diagnosis that go to dermatologic and/or rheumatologic centers or primary care centers. 2. patients that receive pharmacologic treatment for their condition 3. patients that give their written consent to participate
a study of foscarnet in the treatment of cytomegalovirus (cmv) of the eyes in patients with aids

Conditions: Cytomegalovirus Retinitis; HIV Infections

Summary: to evaluate the safety and efficacy of foscarnet induction therapy for treatment of aids patients experiencing their first episode of cytomegalovirus (cmv) retinitis. to evaluate the safety and efficacy of foscarnet maintenance therapy for treatment of aids patients experiencing cmv retinitis.


Eligibility criteria:
inclusion criteria prior medication: allowed: * ganciclovir (dhpg). exclusion criteria co-existing condition: patients with the following are excluded: * any clinically significant pulmonary or neurologic impairment (e.g., patients who are intubated or comatose). * corneal, lens, or vitreous opacification which precludes examination of the fundi, or evidence of tuberculotic, diabetic, and/or hypertensive retinopathy. * known allergy to foscarnet. concurrent medication: excluded: * nephrotoxic drugs. * acyclovir. patients with the following are excluded: * any clinically significant pulmonary or neurologic impairment (e.g., patients who are intubated or comatose). * corneal, lens, or vitreous opacification which precludes examination of the fundi, or evidence of tuberculotic, diabetic, and/or hypertensive retinopathy. * known allergy to foscarnet. prior medication: excluded within 7 days of study entry: * immunomodulators. * biologic response modifiers. * investigational agents (other than ganciclovir). patients with aids as defined by the cdc, with manifest first episode cytomegalovirus (cmv) retinitis as identified by its characteristic ophthalmoscopic appearance and verified by fundus photography. * patients must be able to give informed consent. * patients who enter the study because of ganciclovir toxicity will have received ganciclovir therapy which resulted in either absolute neutrophil count falling to \< 750 cells/mm3 or platelet count falling to \< 50000 platelets/mm3 on two separate occasions during either: * a ganciclovir induction regimen of 7.5 mg (or more)/kg/day in divided doses. * a maintenance regimen of 5 mg (or more)/kg/day as a single daily dose. * patients who enter the study because of ganciclovir treatment failure will meet one of the following criteria: * cmv retinitis progression has occurred either 1) at the end of a 10 - 21 day induction course of ganciclovir (7.5 - 10 mg/kg/day in divided doses) or 2) during the first 28 days of maintenance ganciclovir therapy (5 mg (or more)/kg/day, at least 5 days/week) where maintenance therapy began within 1 week of completing induction therapy.

Keywords: retinitis aids-related opportunistic infections foscarnet cytomegalovirus infections acquired immunodeficiency syndrome
comparison of sliding hip screw to intra medullary nailing in the treatment of intertrochanteric hip fracture

Conditions: Hip Fractures; Gait, Unsteady; Function

Summary: shortening of the abductor lever arm is a particular concern with the shs, and the resultant biomechanical alterations may impair gait, including decreased cadence, gait speed and increased double support time on the injured side. the use of an im nail device may reduce shortening and improve functional parameters in this patient cohort

published work in this field to date has not demonstrated an advantage of nailing over hip screw in intertrochanteric proximal femoral fractures. the current literature focus on outcome questionnaires, pain scores and basic functional tests alone may not delineate all functional benefits. a key factor in whether a person, post hip fracture, returns to independent living is gait speed. the cost implications on the healthcare provider of having 30% of this ever increasing group losing their independence and requiring admission to a care facility post hip fracture is a growing problem. shortening of the abductor lever arm is a particular concern with the shs, and the resultant biomechanical alterations may impair gait, including decreased cadence and increased double support time on the injured side. the cost differential between a nail and a shs is a barrier to routine use of nailing in this population unless a clear benefit is demonstrated. fracture nonunion is uncommon in this injury however improving functional outcome and reducing morbidity and mortality in this group is important. in this prospective randomised study, the investigators examine whether an intramedullary nail (tfna) results in a greater functional benefit in a1/a2 intertrochanteric fractures compared with the shs, in terms of gait speed and other objective gait assessments, as well as other established post operative outcome measures.

Eligibility criteria:
inclusion criteria: * ota hip fracture grade a1 and a2 * greater than 18 years old exclusion criteria: * fracture less than 18 yrs old * fracture with lateral wall trochanteric comminution * poltrauma * concurrent lower limb fractures * immobile/wheelchair/bedbound patients * high energy hip fractures * pathological fractures * reverse oblique and sub-trochanteric femoral fractures which are considered obligate tfna at our centre * open wounds on affected limb * active psoriasis or other dermatological conditions at affected area * unable to gain consent from patient or patient's nok

Keywords: timed up and go mobility functional outcome
brief group intervention using eft (emotional freedom techniques) for depression in college students

Conditions: Depression

Summary: depression is an important mental health concern in college students. this study will recruit students who test positive for moderate to severe depression on the beck depression inventory (bdi). subjects will be randomly assigned to either a treatment or a control condition. those in the treatment group will receive four 90 minute group classes using eft (emotional freedom techniques) to address traumatic memories and other self-identified causes of depression. it will compare them to a no treatment control group.


Eligibility criteria:
inclusion criteria: * a score of 19 or more on the beck depression inventory * currently enrolled at the university of santo tomas * able to read, understand, and complete forms exclusion criteria: * none

Keywords: students, depression, group therapy, eft (emotional freedom techniques), energy psychology
transcranial low voltage pulsed electromagnetic fields (t-pemf) in patients with parkinson's disease

Conditions: Parkinson Disease

Summary: the aim of this study, is to determine whether treatment using transcranial low voltage pulsed electromagnetic fields (t-pemf) can reduce the symptoms patients with parkinson's disease (pd) experience. the symptoms include movement, mentality and the nervous system in general. furthermore the purpose of this study is to clarify whether a group of patients with pd, gain a statistical improvement in their symptoms when treated with active t-pemf, compared to a group of patients with pd who receive placebo t-pemf .


Eligibility criteria:
inclusion criteria: * patients with idiopathic parkinson's disease h \& y 1-3 (hoehn\&yahr) * mmse \> 22 (a screening test for dementia). (mmse - mini-mental state examination) * age \> 18 years. * the patient is capable understanding, accepting and complete the planned procedures. exclusion criteria: * the patient has been using t-pemf before. * changes in anti-parkinson drug treatment within the last 6 weeks * noticeable dementia or other brain injury, which may affect the ability to give consent, or complicates the assessment of the patient * psychosis, or other psychopathological conditions, which requires intervention * the abuse of alcohol or drugs * treatment with deep brain stimulation. * pregnancy or nursing * epilepsy. * active implants such as pacemakers and others for example cochlear implants * active medical device for example insulin pumps, baclofen pumps. * participation in other trials in the intervention period * current or previous history of brain tumors, leukemia, malignant melanoma, skin cancer, or head and neck cancer * autoimmune disease * wounds in the scalp
efficacy of motor control exercise program after lumbar spinal decompression surgery

Conditions: Lumbar Spine Disease

Summary: the study will be conducted with volunteer patients who have undergone lumbar decompression surgery and who are followed up by the neurosurgery outpatient clinic of fethiye state hospital. the cases will be divided into 2 groups by randomization software. the control group will receive stretching, strengthening, core stabilization and educational content as usual care 3 months post-operatively. the study group will be given motion control exercises in addition to the program given to the control group 3 months post-operatively. these applications will be applied to the patients face-to-face in the clinical environment 2 days a week for 12 weeks. the first evaluation will be performed 3 months post-operatively before the treatment and the second evaluation will be performed 3 months after the treatment.


Eligibility criteria:
inclusion criteria: * to have undergone lumbar decompression surgery without fusion and 3 months have passed, to participate in all necessary follow-up evaluations and treatment sessions * to be between the ages of 18-65, to be able to understand simple commands and to have signed the consent form exclusion criteria: * presence of a previous spinal fusion surgery, presence of malignancy * having undergone spine surgery before * have any other orthopedic or neurological problem that may affect treatment and assessments * situations that may interfere with communication * lack of cooperation during the study and refusal to participate in the study
screening for studies on inherited eye diseases

Conditions: Hereditary Eye Disease

Summary: this screening protocol is designed to help recruit patients for national eye institute (nei) studies on inherited eye diseases. patients must meet specific requirements of a research study, and this protocol serves as a first step for admitting patients to an appropriate program. candidates will undergo a medical history, physical examination, eye examination and blood test. the eye examination includes measurement of eye pressure and dilation of the pupils to fully examine the lens, vitreous and retina. specialized tests will be done only if needed to determine eligibility for a specific study in nei's ophthalmic genetics clinic. these include routine laboratory tests, non-invasive imaging, questionnaires and other standard tests, as well as specialized tests and procedures where needed, including genetic testing. photographs of the eye may be taken. patients will be asked questions about family history, especially relating to eye disease or cataracts, and a family tree will be drawn. a blood sample will also be drawn. when the screening is completed, patients will be informed of their options to participate in a study. patients who are ineligible for a current study will be informed of alternative treatments or options. no treatment is offered under this protocol.

this protocol is designed for the screening of patients with either diagnosed or undiagnosed conditions, and serves as a first step for individuals who may be eligible, and wish to participate in nei clinical research studies. each individual will be thoroughly evaluated during the screening process to determine if they are suitable candidates for inclusion in any of the nei ongoing studies. the screening evaluation will include past and current medical histories, and an appropriate physical examination. other routine diagnostic procedures and tests may also be completed in order to help determine a subject's eligibility. these tests and procedures are of minimal risk and will be described in more detail in section iii: "study procedures". once the screening process is completed and their eligibility is assessed, the subjects will be informed of their options to participate in one or more of the current clinical research studies. if no appropriate protocol is identified, recommendations for other treatment options may be given to the individual, their primary doctor, or referring physician.

Eligibility criteria:
* inclusion criteria: inclusion and exclusion criteria vary with the particular protocol for which a patient is being screened. in addition to those diagnoses currently under study, subjects with unusual, interesting, or unknown conditions that require the establishment of a diagnosis, may be eligible for inclusion in this study. the subjects source for this study will be from referrals by medical practitioners in the private sector, clinics, hospitals, medical institutions, and the occupational medical services at the national institutes of health

Keywords: genetics diagnosis screening protocol ophthalmic genetic diseases genetic testing family studies
a study assessing the safety and utility of pinpoint® near infrared fluorescence imaging in the identification of lymph nodes in patients with uterine and cervical malignancies who are undergoing lymph node mapping

Conditions: Endometrial Cancer; Uterine Cancer; Cervical Cancer

Summary: this is a randomized, prospective, open label, multicenter study to assess the safety and utility of pinpoint® near infrared fluorescence imaging (pinpoint) in identification of lymph nodes (ln) in patients with uterine and cervical malignancies who are undergoing ln mapping.


Eligibility criteria:
inclusion criteria: * 18 years of age or older * subjects with figo clinical stage i endometrial cancer undergoing minimally invasive hysterectomy with lymph node mapping. * subjects with figo clinical stage ia cervical cancer ≤ 2 cm in size undergoing minimally invasive hysterectomy, trachelectomy, or conization with lymph node mapping. subjects with clinical stage ia1 cervical cancer without lympho vascular space involvement (lvsi) and negative margins on cone biopsy are not to be included. * subjects with negative nodal status (n0) * subjects with negative metastatic involvement (m0). exclusion criteria: * have had prior dissection and/or radiation in pelvis. * advanced cervical or endometrial cancer, t3/t4 lesions * diagnosis of cervical cancer with a tumor size greater than 2 cm. * locally advanced or inflammatory cervical or uterine cancer * metastatic cervical or uterine cancer. * known allergy or history of adverse reaction to icg, iodine or iodine dyes. * known allergy or history of adverse reaction to blue dye (isosulfan blue) or triphenylmethane. * hepatic dysfunction defined as meld score \> 12. * renal dysfunction defined as serum creatinine ≥ 2.0 mg/dl. * subjects who have participated in another investigational study within 30 days prior to surgery. * pregnant or lactating subjects. * subjects who, in the investigator's opinion, have any medical condition that makes the subject a poor candidate for the investigational procedure, or interferes with the interpretation of study results.

Keywords: lymph node mapping endometrial cancer uterine cancer cervical cancer
tenofovir, emtricitabine and efavirenz late switch to a single pill: patients' opinion survey

Conditions: HIV Infection

Summary: the purpose of this study is to assess adherence, tolerability and satisfaction of each eligible hiv subjects switching from a two- or three-pill tenofovir-emtricitabine-efavirenz (tdf-ftc-efv) to a one-pill tdf-ftc-efv treatment.

each eligible patient will be screened from de shcs database. each refusal and drop-out will be documented. a pre-visit (v-1) will be scheduled for informed consent, v0 for inclusion (v-1 and v0 may occur on the same day), v1 one month post-inclusion and v2 4 to 7 months post-inclusion. v0, v1 and v2 will be planned during regular medical visits. eligible patients either get their cart in their usual pharmacy according to standard of care, or take part in a routine adherence-enhancing program(adherence subgroup)run by the pharmacists of the outpatient medical clinic. in the adherence subgroup, adherence is assessed electronically by mems (medication event monitoring system) monitors on a regular basis.

Eligibility criteria:
inclusion criteria: * patients under tdf-ftc-efv * followed up at the service of infectious disease of the university hospital of lausanne * enrolled in the shcs exclusion criteria: * patients receiving tdf-ftc-efv in combination with other arts * patients under tdf-ftc-efv for less than 3 months * patients not fluent in french

Keywords: medication adherence hiv infection efavirenz, emtricitabine, tenofovir disoproxil fumarate drug combination [substance name] efavirenz emtricitabine patient satisfaction tenofovir disoproxil fumarate
comparison of two silicone hydrogel toric contact lenses

Conditions: Astigmatism

Summary: the purpose of this research study is to compare the performance of two different types of alcon soft toric study contact lenses to obtain information on study lens orientation.


Eligibility criteria:
inclusion criteria: * successful wear of soft contact lenses for vision correction in both eyes during the past 3 months for a minimum of 3 days per week and 8 hours per day * astigmatism * requires contact lenses * best corrected visual acuity of 20/25 or better in each eye * other protocol-specified inclusion criteria may apply exclusion criteria: * any eye condition that contraindicates contact lens wear, as determined by the investigator * any eye surgery that contraindicates contact lens wear, as determined by the investigator * other protocol-specified exclusion criteria may apply

Keywords: astigmatism axis orientation
integrative analysis of human glioblastoma multiforme

Conditions: GBM

Summary: integrative analysis of gbm

the investigators will analyzed proteomes of paired normal brain tissues and gbm, sequenced transcriptomes, perform whole exome sequencing, and single nucleotide polymorphism (snp) array profiling for triplets, each comprising normal brain tissue, primary gbm carcinoma, and its synchronous matched metastasis, as well as analyzed genomics of gbm characterized previously by the cancer genome atlas (tcga) to conduct integrated proteogenomic analyses.

Eligibility criteria:
inclusion criteria: * age ≤ 75 years with histologically proven gbm * no severe major organ dysfunction * world health organization (who) performance status of 0 or 1 * no prior cancer chemotherapy exclusion criteria: * age ≥ 76 * severe major organ dysfunction * who performance status of \>1 * prior cancer chemotherapy

Keywords: gbm; integrative analysis; wes